• Country / Location Selection

United States (US)

GeneTex Partners With BenchSci to Augment Antibody Catalog Publication Data

Partnership will use BenchSci's artificial intelligence to help researchers run successful experiments with the right antibodyPartnership will use BenchSci's artificial intelligence to help researchers run successful experiments with the right antibody

IRVINE, Calif., November 19, 2018 ( - GeneTex, Inc., a research antibody manufacturer, and BenchSci, a life science machine learning startup backed by Google’s AI fund, have announced a new partnership to overcome a key challenge that biomedical researchers face when selecting antibody reagents for their experiments.

It is well documented that research antibodies lacking specificity and reliability have resulted in staggering amounts of wasted money, time, and effort, not to mention questionable scientific conclusions. This severely compromises the pace of discovery and slows productivity, with particularly negative implications for progress against disease and other major challenges impacting our society.

To prevent this, researchers review scientific papers for published data on antibodies when planning experiments. However, more than 38 million scientific papers have been published since 1980, a number that doubles every nine years. It can require hours, and sometimes days, to find useful data—if it can be found at all.

GeneTex’s partnership with BenchSci aims to solve this problem by combining the company’s ~50,000-reagent catalog with BenchSci’s industry-leading artificial intelligence platform. BenchSci will use machine learning to identify published data for individual GeneTex products in open- and closed-access datasets, display related published figures, and allow researchers to search using important experimental variables.

Allen Lee, Vice President of Business Development at GeneTex, believes that this relationship with BenchSci represents another component of his company’s constant effort to offer better validation of its antibody products and to assist scientists in their selection of the best reagent for a given experimental application. “GeneTex and BenchSci share the same goal,” he notes, “to put the best-suited antibody in the hands of the researcher.”

Liran Belenzon, CEO, BenchSci, says that the partnership will increase discoverability of GeneTex products in more than 1,300 academic institutions and 14 top pharmaceutical companies where researchers rely on BenchSci for their antibody searches. “BenchSci has proven to help researchers find the right antibodies up to 24x faster,” he says. “With our GeneTex partnership, researchers can now also purchase those antibodies faster, further speeding research to drive more rapid discoveries.”

About GeneTex

GeneTex was founded by three internationally renowned scientists with recognized expertise in clinical oncology, cancer biology, and infectious diseases. Its product portfolio has since expanded to cover research areas including cancer, cell biology, epigenetics, immunology, infectious disease, metabolism, neuroscience, signal transduction, stem cell development, and zebrafish biology. With the construction of a state-of-the-art high-capacity manufacturing facility, GeneTex is now a multinational organization and one of the largest antibody manufacturers with a global distribution network. GeneTex is proud to offer the highest quality antibody reagents supported by extensive research, development, and validation, with the explicit goal of accelerating biomedical discovery. For more information, please visit our website (

About BenchSci

BenchSci decodes the world’s biological data to reduce the time, uncertainty, and cost of biomedical research. Researchers waste time and money on antibodies that don't work. These slow studies often lead to the destruction of samples and leaves patients waiting for treatment. Artificial intelligence can solve the problem, and BenchSci is building it. BenchSci’s technology helps researchers find reliable antibodies 24x faster and 75 percent cheaper. Backed by Google’s AI fund, BenchSci applies machine learning to decode comprehensive open- and closed-access datasets, display published figures with no commercial bias, and allow researchers to search by important experimental variables. BenchSci now powers discoveries in 14 of the top 20 pharmaceutical companies and 1,300 academic institutions. Academic researchers can sign up free at Industry researchers can request a demo at

Contact: Simon Smith, Chief Growth Officer, BenchSci,, 416-738-6058.